Vancouver, B.C. August 16, 2011 –Yellow Point Equity Partners Limited Partnership (the “Partnership”) is pleased to announce that it has now converted Series A Convertible Subordinated Debentures in the princpal amount of $6,850,000 (the “Debentures”) of Prism Medical Ltd. (“Prism” or the “Company”), which represents all of the Debentures held by the Partnership, into an aggregate 1,826,666 common shares (the “Common Shares”) of the Company at a price of $3.75 per Common Share. The Debentures were originally issued by the Company on September 17, 2004. As a result of the conversion in full of the Debentures, the Partnership has now acquired control of, and holds, an aggregate 1,826,666 Common Shares of the Company, which represents approximately 22% of the current issued and outstanding Common Shares of Prism, assuming no other Common Shares are issued.
The Partnership acquired the Debentures in private transactions in reliance on the exemption from the prospectus requirements contained in section 23 of National Instrument 45-106Prospectus and Registration Exemptions. The Debentures were acquired for investment purposes only and the Partnership may purchase further securities of the Company in the future.
This news release is being issued pursuant to Part 3 of National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues of the Canadian Securities Administrators. A copy of the report filed by the Partnership in connection with the conversion of the Debentures into Common Shares of Prism is available on the Company’s SEDAR profile, and it can also be obtained directly from the Partnership by contacting the representative of the Partnership, Tyler Smyrski, at (604) 659-1892 or email@example.com.